Fresenius SE & Co. (OTCMKTS:FSNUY) Sees Large Growth in Short Interest

Fresenius SE & Co. (OTCMKTS:FSNUY) was the recipient of a large increase in short interest in the month of January. As of January 15th, there was short interest totaling 35,983 shares, an increase of 221.2% from the December 31st total of 11,203 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 179,753 shares, the short-interest ratio is currently 0.2 days. Based on an average daily trading volume, of 179,753 shares, the short-interest ratio is currently 0.2 days. Approximately 0.0% of the shares of the stock are short sold.

Fresenius SE & Co. Stock Down 1.7%

Shares of OTCMKTS FSNUY traded down $0.24 during trading hours on Thursday, hitting $13.99. The stock had a trading volume of 15,094 shares, compared to its average volume of 80,759. The company has a market capitalization of $31.52 billion, a P/E ratio of 25.44 and a beta of 0.76. The firm’s 50-day moving average price is $14.14 and its two-hundred day moving average price is $14.02. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.99 and a current ratio of 1.26. Fresenius SE & Co. has a 52 week low of $9.50 and a 52 week high of $33.93.

Fresenius SE & Co. (OTCMKTS:FSNUY) last posted its earnings results on Wednesday, November 5th. The company reported $0.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.21 by $0.02. The firm had revenue of $6.29 billion during the quarter, compared to analysts’ expectations of $6.38 billion. Fresenius SE & Co. had a net margin of 5.26% and a return on equity of 9.72%. Analysts anticipate that Fresenius SE & Co. will post 0.79 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on FSNUY shares. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Fresenius SE & Co. in a report on Monday, October 27th. Morgan Stanley reaffirmed an “overweight” rating on shares of Fresenius SE & Co. in a research note on Monday, December 15th. Two investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, Fresenius SE & Co. currently has a consensus rating of “Buy”.

Fresenius SE & Co. Company Profile

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.